SWHR offers support to both the President Trump administration and Congress and will actively build on the progress made in advancing women’s health in the U.S. and worldwide.
SWHR thanks the House Appropriators for their continued support of the National Institutes of Health.
Dr. Robert M. Califf, distinguished cardiologist and medical researcher, has been confirmed by the U.S. Senate as the next U.S. Food and Drug Administration (FDA) Commissioner. President Barack Obama nominated Dr. Califf in September 2015.
The United States Senate Committee on Health, Education, Labor and Pensions (HELP) unanimously approved Dr. Robert Califf's nomination to serve as U.S. Food and Drug Administration (FDA) Commissioner, moving the process to the full Senate for a final vote.
Longtime supporter of women’s health research Senator Barbara A. Mikulski (D-Md.) will be awarded a Presidential Medal of Freedom, the nation’s highest civilian honor, on November 24th at a ceremony at the White House.
The Bipartisan Budget Act of 2016 replaces sequestration equally for both defense and nondefense over the next two years. Failure to pass this critical legislation will hinder scientific discovery, compromise public health programs, and delay patients’ access to innovative medical treatments.
The Government Accountability Office (GAO) released a report, showing that more work needs to be done in reporting and analysis policies to further ensure women and minorities are being accurately represented in clinical trials.
President Barack Obama has nominated distinguished cardiologist and medical researcher Dr. Robert Califf to be the next U.S. Food and Drug Administration (FDA) Commissioner.
SWHR applauds the Food and Drug Administration (FDA) on the approval of Flibanserin, the first ever medical treatment option for Hypoactive Sexual Desire Disorder (HSDD).
SWHR supports the National Institute of Health’s (NIH) move to include sex as a biological variable in future research.